Locally Advanced Pancreatic Cancer

Also known as: Pancreatic Carcinoma Stage II / Locally advanced Pancreatic cancer

DrugDrug NameDrug Description
DB00530ErlotinibErlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
DrugDrug NamePhaseStatusCount
DB01101Capecitabine1 / 2Completed1
DB00441Gemcitabine1 / 2Completed1
DB00441Gemcitabine1 / 2Recruiting2
DB00526Oxaliplatin1 / 2Completed1
DB00530Erlotinib2Completed1
DB00544Fluorouracil2Unknown Status1
DB00441Gemcitabine2Completed2
DB00441Gemcitabine2Unknown Status2
DB00650Leucovorin2Unknown Status1
DB05477MUC1 Dendritic Cell Vaccine2Withdrawn1
DB00331Metformin2Completed1
DB00526Oxaliplatin2Completed1
DB00526Oxaliplatin2Unknown Status1
DB09256Tegafur2Not Yet Recruiting1
DB06361rsPSMA Vaccine2Withdrawn1
DB00758Clopidogrel3Active Not Recruiting1
DB00441Gemcitabine3Completed1
DB00441Gemcitabine3Recruiting1
DB00762Irinotecan3Recruiting1
DB00441Gemcitabine4Recruiting1
DB01229Paclitaxel4Recruiting1
DB00441GemcitabineNot AvailableRecruiting1